Satoru Tada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Satoru Tada has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Hideki Mochizuki
Affiliation Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
8 shared publicationsMakoto Kinoshita
Department of Neurology, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
7 shared publicationsToru Koda
Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
6 shared publicationsKazushiro Takata
Department of Neurology, Hoshigaoka Medical Center, Hirakata, Osaka, Japan
5 shared publicationsTatsusada Okuno
Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
5 shared publications- Tatsusada Okuno
Department of Neurology, Graduate School of Medicine, The University of Osaka, Japan
5 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (6) , e0001530
A single-camera video-based assessment of locomotive syndrome using pose-silhouette fusion model
Locomotive syndrome (LS), characterized by declining mobility due to musculoskeletal disorders, significantly affects older adults and is highly prevalent in Japan. Early detection and intervention are crucial to mitigate disease progression and preserve quality of life. Current diagnostic methods rely on subjective self-reports and labor-intensive clinical assessments, underscoring the need for automated, objective, and scalable screening tools. Building on our previous work, this study presents an updated deep learning-based computer vision model for LS screening using single-camera walking videos. We collected 511 walking videos from 178 participants clinically classified into four LS stages (non-LS, stage 1, stage 2, and stage 3). We used the MMPose framework to extract 2D body keypoints and generated silhouette-based Gait Energy Images (GEIs) from seven frames automatically sampled from fixed 40-frame walking windows to capture complementary gait-shape information. Model performance was evaluated using 10-fold cross-validation based on held-out evaluation-window predictions, while ensuring that windows from the same participant and the same walking video were not split across training, validation, and test sets. We also evaluated an independent external validation cohort of 33 cases (LS0–1, n = 15; LS2–3, n = 18). In internal validation, the pose-estimation model achieved sensitivity of 0.9440 and an AUC of 0.9668, whereas the silhouette model showed specificity of 0.9085 and an AUC of 0.9191. Fusion models outperformed the individual approaches, with the highest F1-score (0.908) at a 60:40 pose-to-silhouette ratio and the highest AUC (0.971) at a 70:30 ratio. In external validation, the score-fusion model achieved 90.9% accuracy, 88.9% sensitivity, 93.3% specificity, a macro-F1 score of 0.909, and an AUC of 0.967. In conclusion, integrating pose-estimation and silhouette-based features substantially improves the accuracy and clinical utility of automated LS screening. This low-burden approach provides a practical bridge between population-level screening and definitive clinical assessment.
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (6) , e0001530
Open AccessA single-camera video-based assessment of locomotive syndrome using pose-silhouette fusion model
Locomotive syndrome (LS), characterized by declining mobility due to musculoskeletal disorders, significantly affects older adults and is highly prevalent in Japan. Early detection and intervention are crucial to mitigate disease progression and preserve quality of life. Current diagnostic methods rely on subjective self-reports and labor-intensive clinical assessments, underscoring the need for automated, objective, and scalable screening tools. Building on our previous work, this study presents an updated deep learning-based computer vision model for LS screening using single-camera walking videos. We collected 511 walking videos from 178 participants clinically classified into four LS stages (non-LS, stage 1, stage 2, and stage 3). We used the MMPose framework to extract 2D body keypoints and generated silhouette-based Gait Energy Images (GEIs) from seven frames automatically sampled from fixed 40-frame walking windows to capture complementary gait-shape information. Model performance was evaluated using 10-fold cross-validation based on held-out evaluation-window predictions, while ensuring that windows from the same participant and the same walking video were not split across training, validation, and test sets. We also evaluated an independent external validation cohort of 33 cases (LS0–1, n = 15; LS2–3, n = 18). In internal validation, the pose-estimation model achieved sensitivity of 0.9440 and an AUC of 0.9668, whereas the silhouette model showed specificity of 0.9085 and an AUC of 0.9191. Fusion models outperformed the individual approaches, with the highest F1-score (0.908) at a 60:40 pose-to-silhouette ratio and the highest AUC (0.971) at a 70:30 ratio. In external validation, the score-fusion model achieved 90.9% accuracy, 88.9% sensitivity, 93.3% specificity, a macro-F1 score of 0.909, and an AUC of 0.967. In conclusion, integrating pose-estimation and silhouette-based features substantially improves the accuracy and clinical utility of automated LS screening. This low-burden approach provides a practical bridge between population-level screening and definitive clinical assessment.
- Open Access
- 26 November 2024
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 3 (11) , e0000668
Deep learning-based screening for locomotive syndrome using single-camera walking video: Development and validation study
Locomotive Syndrome (LS) is defined by decreased walking and standing abilities due to musculoskeletal issues. Early diagnosis is vital as LS can be reversed with appropriate intervention. Although diagnosing LS using standardized charts is straightforward, the labor-intensive and time-consuming nature of the process limits its widespread implementation. To address this, we introduced a Deep Learning (DL)-based computer vision model that employs OpenPose for pose estimation and MS-G3D for spatial-temporal graph analysis. This model objectively assesses gait patterns through single-camera video captures, offering a novel and efficient method for LS prediction and analysis. Our model was trained and validated using a dataset of 186 walking videos, plus 65 additional videos for external validation. The model achieved an average sensitivity of 0.86, demonstrating high effectiveness in identifying individuals with LS. The model’s positive predictive value was 0.85, affirming its reliable LS detection, and it reached an overall accuracy rate of 0.77. External validation using an independent dataset confirmed strong generalizability with an Area Under the Curve of 0.75. Although the model accurately diagnosed LS cases, it was less precise in identifying non-LS cases. This study pioneers in diagnosing LS using computer vision technology for pose estimation. Our accessible, non-invasive model serves as a tool that can accurately diagnose the labor-intensive LS tests using only visual assessments, streamlining LS detection and expediting treatment initiation. This significantly improves patient outcomes and marks a crucial advancement in digital health, addressing key challenges in management and care of LS.
- 26 November 2024
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 3 (11) , e0000668
Open AccessDeep learning-based screening for locomotive syndrome using single-camera walking video: Development and validation study
Locomotive Syndrome (LS) is defined by decreased walking and standing abilities due to musculoskeletal issues. Early diagnosis is vital as LS can be reversed with appropriate intervention. Although diagnosing LS using standardized charts is straightforward, the labor-intensive and time-consuming nature of the process limits its widespread implementation. To address this, we introduced a Deep Learning (DL)-based computer vision model that employs OpenPose for pose estimation and MS-G3D for spatial-temporal graph analysis. This model objectively assesses gait patterns through single-camera video captures, offering a novel and efficient method for LS prediction and analysis. Our model was trained and validated using a dataset of 186 walking videos, plus 65 additional videos for external validation. The model achieved an average sensitivity of 0.86, demonstrating high effectiveness in identifying individuals with LS. The model’s positive predictive value was 0.85, affirming its reliable LS detection, and it reached an overall accuracy rate of 0.77. External validation using an independent dataset confirmed strong generalizability with an Area Under the Curve of 0.75. Although the model accurately diagnosed LS cases, it was less precise in identifying non-LS cases. This study pioneers in diagnosing LS using computer vision technology for pose estimation. Our accessible, non-invasive model serves as a tool that can accurately diagnose the labor-intensive LS tests using only visual assessments, streamlining LS detection and expediting treatment initiation. This significantly improves patient outcomes and marks a crucial advancement in digital health, addressing key challenges in management and care of LS.
- Open Access
- 23 February 2024
- Published by Springer Nature in Cureus
- Vol. 16 (2) , e54775
Varicella-Zoster Meningitis and Myelitis After Herpes Zoster Dermatitis Treatment With Amenamevir: A Case Series and Literature Review
Varicella-zoster virus (VZV), known for causing chickenpox, establishes latent infections in neural tissues. Reactivation of VZV can lead to herpes zoster (HZ) and various neurological complications. In this report, we present four cases of VZV meningitis and myelitis following amenamevir treatment for HZ dermatitis with positive VZV DNA in cerebrospinal fluid (CSF) revealed by polymerase chain reaction (PCR). Three of them were considered immunocompromised hosts given the fact that two of these patients were taking immunosuppressive drugs for rheumatoid arthritis, and one patient had a history of sigmoid colon cancer (four months after resection). After HZ onset, amenamevir, which has poor CSF transfer, was prescribed for all the patients, and all of them developed central nervous complications by VZV (meningitis in three cases and myelitis in one case) confirmed by PCR. All the patients were treated with acyclovir, which has a higher CSF transfer, and fully recovered. We speculate that amenamevir might have failed to prevent VZV infection in the central nervous system (CNS) and think that consideration should be given to administering acyclovir in preference to amenamevir for ΗΖ patients at high risk of CNS VZV infection, such as immunocompromised hosts.
- 23 February 2024
- Published by Springer Nature in Cureus
- Vol. 16 (2) , e54775
Open AccessVaricella-Zoster Meningitis and Myelitis After Herpes Zoster Dermatitis Treatment With Amenamevir: A Case Series and Literature Review
Varicella-zoster virus (VZV), known for causing chickenpox, establishes latent infections in neural tissues. Reactivation of VZV can lead to herpes zoster (HZ) and various neurological complications. In this report, we present four cases of VZV meningitis and myelitis following amenamevir treatment for HZ dermatitis with positive VZV DNA in cerebrospinal fluid (CSF) revealed by polymerase chain reaction (PCR). Three of them were considered immunocompromised hosts given the fact that two of these patients were taking immunosuppressive drugs for rheumatoid arthritis, and one patient had a history of sigmoid colon cancer (four months after resection). After HZ onset, amenamevir, which has poor CSF transfer, was prescribed for all the patients, and all of them developed central nervous complications by VZV (meningitis in three cases and myelitis in one case) confirmed by PCR. All the patients were treated with acyclovir, which has a higher CSF transfer, and fully recovered. We speculate that amenamevir might have failed to prevent VZV infection in the central nervous system (CNS) and think that consideration should be given to administering acyclovir in preference to amenamevir for ΗΖ patients at high risk of CNS VZV infection, such as immunocompromised hosts.
- Open Access
- 24 November 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (47) , eadg3193
RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS
Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone–collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we demonstrated that RGMa concentration was elevated in the cerebrospinal fluid of both patients with ALS and transgenic mice overexpressing the mutant human superoxide dismutase1 (mSOD1 mice). Treatment with humanized anti-RGMa monoclonal antibody ameliorated the clinical symptoms in mSOD1 mice. Histochemical analysis revealed that the anti-RGMa antibody significantly decreased mutant SOD1 protein accumulation in the motor neurons of mSOD1 mice via inhibition of actin depolymerization. In vitro analysis revealed that the anti-RGMa antibody inhibited the cellular uptake of the mutant SOD1 protein, presumably by reinforcing the neuronal actin barrier. Collectively, these data suggest that RGMa leads to the collapse of the neuronal actin barrier and promotes aberrant protein deposition, resulting in exacerbation of the ALS pathology.
- 24 November 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (47) , eadg3193
Open AccessRGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS
Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone–collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we demonstrated that RGMa concentration was elevated in the cerebrospinal fluid of both patients with ALS and transgenic mice overexpressing the mutant human superoxide dismutase1 (mSOD1 mice). Treatment with humanized anti-RGMa monoclonal antibody ameliorated the clinical symptoms in mSOD1 mice. Histochemical analysis revealed that the anti-RGMa antibody significantly decreased mutant SOD1 protein accumulation in the motor neurons of mSOD1 mice via inhibition of actin depolymerization. In vitro analysis revealed that the anti-RGMa antibody inhibited the cellular uptake of the mutant SOD1 protein, presumably by reinforcing the neuronal actin barrier. Collectively, these data suggest that RGMa leads to the collapse of the neuronal actin barrier and promotes aberrant protein deposition, resulting in exacerbation of the ALS pathology.
- Open Access
- 13 July 2022
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (8) , e14759
Genetically modified macrophages accelerate myelin repair
Preventing neurodegeneration‐associated disability progression in patients with multiple sclerosis (MS) remains an unmet therapeutic need. As remyelination prevents axonal degeneration, promoting this process in patients might enhance neuroprotection. In demyelinating mouse lesions, local overexpression of semaphorin 3F (Sema3F), an oligodendrocyte progenitor cell (OPC) attractant, increases remyelination. However, molecular targeting to MS lesions is a challenge. A clinically relevant paradigm for delivering Sema3F to demyelinating lesions could be to use blood‐derived macrophages as vehicles. Thus, we chose transplantation of genetically modified hematopoietic stem cells (HSCs) as means of obtaining chimeric mice with circulating Sema3F‐overexpressing monocytes. We demonstrated that Sema3F‐transduced HSCs stimulate OPC migration in a neuropilin 2 (Nrp2, Sema3F receptor)‐dependent fashion, which was conserved in middle‐aged OPCs. While demyelinating lesions induced in mice with Sema3F‐expressing blood cells showed no changes in inflammation and OPC survival, OPC recruitment was enhanced which accelerated the onset of remyelination. Our results provide a proof of concept that blood cells, particularly monocytes/macrophages, can be used to deliver pro‐remyelinating agents “at the right time and place,” suggesting novel means for remyelination‐promoting strategies in MS.
- 13 July 2022
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (8) , e14759
Open AccessGenetically modified macrophages accelerate myelin repair
Preventing neurodegeneration‐associated disability progression in patients with multiple sclerosis (MS) remains an unmet therapeutic need. As remyelination prevents axonal degeneration, promoting this process in patients might enhance neuroprotection. In demyelinating mouse lesions, local overexpression of semaphorin 3F (Sema3F), an oligodendrocyte progenitor cell (OPC) attractant, increases remyelination. However, molecular targeting to MS lesions is a challenge. A clinically relevant paradigm for delivering Sema3F to demyelinating lesions could be to use blood‐derived macrophages as vehicles. Thus, we chose transplantation of genetically modified hematopoietic stem cells (HSCs) as means of obtaining chimeric mice with circulating Sema3F‐overexpressing monocytes. We demonstrated that Sema3F‐transduced HSCs stimulate OPC migration in a neuropilin 2 (Nrp2, Sema3F receptor)‐dependent fashion, which was conserved in middle‐aged OPCs. While demyelinating lesions induced in mice with Sema3F‐expressing blood cells showed no changes in inflammation and OPC survival, OPC recruitment was enhanced which accelerated the onset of remyelination. Our results provide a proof of concept that blood cells, particularly monocytes/macrophages, can be used to deliver pro‐remyelinating agents “at the right time and place,” suggesting novel means for remyelination‐promoting strategies in MS.
- Open Access
- 21 February 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (3) , 517-527
Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain
Hematopoietic stem cell transplantation (HSCT) is a therapy used for multiple malignant and nonmalignant diseases, with chemotherapy used for pretransplantation myeloablation. The post-HSCT brain contains peripheral engrafted parenchymal macrophages, despite their absence in the normal brain, with the engraftment mechanism still undefined. Here we show that HSCT chemotherapy broadly disrupts mouse brain regenerative populations, including a permanent loss of adult neurogenesis. Microglial density was halved, causing microglial process expansion, coinciding with indicators of broad senescence. Although microglia expressed cell proliferation markers, they underwent cell cycle arrest in S phase with a majority expressing the senescence and antiapoptotic marker p21. In vivo single-cell tracking of microglia after recovery from chemical depletion showed loss of their regenerative capacity, subsequently replaced with donor macrophages. We propose that HSCT chemotherapy causes microglial senescence with a gradual decrease to a critical microglial density, providing a permissive niche for peripheral macrophage engraftment of the brain.
- 21 February 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (3) , 517-527
Open AccessHematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain
Hematopoietic stem cell transplantation (HSCT) is a therapy used for multiple malignant and nonmalignant diseases, with chemotherapy used for pretransplantation myeloablation. The post-HSCT brain contains peripheral engrafted parenchymal macrophages, despite their absence in the normal brain, with the engraftment mechanism still undefined. Here we show that HSCT chemotherapy broadly disrupts mouse brain regenerative populations, including a permanent loss of adult neurogenesis. Microglial density was halved, causing microglial process expansion, coinciding with indicators of broad senescence. Although microglia expressed cell proliferation markers, they underwent cell cycle arrest in S phase with a majority expressing the senescence and antiapoptotic marker p21. In vivo single-cell tracking of microglia after recovery from chemical depletion showed loss of their regenerative capacity, subsequently replaced with donor macrophages. We propose that HSCT chemotherapy causes microglial senescence with a gradual decrease to a critical microglial density, providing a permissive niche for peripheral macrophage engraftment of the brain.
- Open Access
Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma
Myasthenia gravis (MG) is a neurological disease caused by autoantibodies against neuromuscular-associated proteins. While MG is frequently developed in thymoma patients, the etiologic factors for MG are not well understood. Here, by constructing a comprehensive atlas of thymoma using bulk and single-cell RNA-seq, we identified ectopic expression of neuromuscular molecules in MG-associated thymoma (MG-thymoma). These molecules were originated from a distinct subpopulation of medullary thymic epithelial cells (mTECs), which we named neuromuscular mTECs (nmTECs). MG-thymoma also exhibited microenvironments dedicated to autoantibody production, including ectopic germinal center formation, T follicular helper cell accumulation, and type 2 conventional dendritic cell migration. Cell-cell interaction analysis also predicted the interaction between nmTECs and T/B cells via CXCL12 - CXCR4 . The enrichment of nmTECs presenting neuromuscular molecules within MG-thymoma was further confirmed by immunohistochemically and by cellular composition estimation from MG-thymoma transcriptome. Altogether, this study suggests that nmTECs play a significant role in MG pathogenesis via ectopic expression of neuromuscular molecules.
Open AccessMyasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma
Myasthenia gravis (MG) is a neurological disease caused by autoantibodies against neuromuscular-associated proteins. While MG is frequently developed in thymoma patients, the etiologic factors for MG are not well understood. Here, by constructing a comprehensive atlas of thymoma using bulk and single-cell RNA-seq, we identified ectopic expression of neuromuscular molecules in MG-associated thymoma (MG-thymoma). These molecules were originated from a distinct subpopulation of medullary thymic epithelial cells (mTECs), which we named neuromuscular mTECs (nmTECs). MG-thymoma also exhibited microenvironments dedicated to autoantibody production, including ectopic germinal center formation, T follicular helper cell accumulation, and type 2 conventional dendritic cell migration. Cell-cell interaction analysis also predicted the interaction between nmTECs and T/B cells via CXCL12 - CXCR4 . The enrichment of nmTECs presenting neuromuscular molecules within MG-thymoma was further confirmed by immunohistochemically and by cellular composition estimation from MG-thymoma transcriptome. Altogether, this study suggests that nmTECs play a significant role in MG pathogenesis via ectopic expression of neuromuscular molecules.
- Open Access
Genetically-Modified Macrophages Accelerate Myelin Repair
Preventing neurodegeneration-associated disability progression in patients with multiple sclerosis (MS) remains an unmet therapeutic need. As remyelination prevents degeneration of demyelinated axons, promoting this process in patients might halt the development of permanent disability. In demyelinating mouse lesions, local overexpression of Semaphorin 3F (Sema3F), an oligodendrocyte progenitor cell (OPC) attractant, increases OPC recruitment and remyelination. However, molecular targeting to MS lesions is a challenge because these are disseminated in the central nervous system. We hypothesized that a clinically-relevant paradigm to deliver Sema3F to demyelinating lesions and increase OPC recruitment may be to use blood-derived macrophages as vehicles. Thus, we chose transplantation of genetically-modified hematopoietic stem cells (HSCs) as means of obtaining circulating monocytes that overexpress Sema3F. We first demonstrated that the supernatant from Sema3F-lentiviral vector transduced HSCs stimulates OPC migration in Neuropilin 2 (Nrp2, Sema3F receptor)-dependent fashion. We then investigated whether OPCs remain responsive to Sema3F with age. While Sema3F expression in the lesions of middle-aged and old mice (characterized by decreased efficiency of OPC recruitment and remyelination) was decreased, middle-aged OPCs retained Nrp2 expression and migrated in response to both recombinant Sema3F and Sema3F-transduced cell supernatant in vitro. We then investigated whether blood cells engineered to overexpress Sema3F can target demyelinating CNS lesions and improve remyelination. Thus, we transplanted Sema3F-transduced HSCs and obtained chimeric mice (with Sema3F overexpression in blood cells), in which we induced demyelinating spinal cord lesions. Transgene-carrying cells, predominantly macrophages, quickly infiltrated lesions in both control and Sema3F chimeras. While infiltration of Sema3F-expressing cells did not alter the inflammatory status of the lesions nor OPC survival, it increased OPC recruitment, which accelerated the onset of remyelination. Our results provide a proof-of-concept that blood cells, particularly monocyte-derived macrophages, can be used to deliver pro-remyelinating agents “at the right time and place”, suggesting novel means for remyelination-promoting strategies.
Open AccessGenetically-Modified Macrophages Accelerate Myelin Repair
Preventing neurodegeneration-associated disability progression in patients with multiple sclerosis (MS) remains an unmet therapeutic need. As remyelination prevents degeneration of demyelinated axons, promoting this process in patients might halt the development of permanent disability. In demyelinating mouse lesions, local overexpression of Semaphorin 3F (Sema3F), an oligodendrocyte progenitor cell (OPC) attractant, increases OPC recruitment and remyelination. However, molecular targeting to MS lesions is a challenge because these are disseminated in the central nervous system. We hypothesized that a clinically-relevant paradigm to deliver Sema3F to demyelinating lesions and increase OPC recruitment may be to use blood-derived macrophages as vehicles. Thus, we chose transplantation of genetically-modified hematopoietic stem cells (HSCs) as means of obtaining circulating monocytes that overexpress Sema3F. We first demonstrated that the supernatant from Sema3F-lentiviral vector transduced HSCs stimulates OPC migration in Neuropilin 2 (Nrp2, Sema3F receptor)-dependent fashion. We then investigated whether OPCs remain responsive to Sema3F with age. While Sema3F expression in the lesions of middle-aged and old mice (characterized by decreased efficiency of OPC recruitment and remyelination) was decreased, middle-aged OPCs retained Nrp2 expression and migrated in response to both recombinant Sema3F and Sema3F-transduced cell supernatant in vitro. We then investigated whether blood cells engineered to overexpress Sema3F can target demyelinating CNS lesions and improve remyelination. Thus, we transplanted Sema3F-transduced HSCs and obtained chimeric mice (with Sema3F overexpression in blood cells), in which we induced demyelinating spinal cord lesions. Transgene-carrying cells, predominantly macrophages, quickly infiltrated lesions in both control and Sema3F chimeras. While infiltration of Sema3F-expressing cells did not alter the inflammatory status of the lesions nor OPC survival, it increased OPC recruitment, which accelerated the onset of remyelination. Our results provide a proof-of-concept that blood cells, particularly monocyte-derived macrophages, can be used to deliver pro-remyelinating agents “at the right time and place”, suggesting novel means for remyelination-promoting strategies.
- Open Access
- 13 March 2020
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 17 (1) , 1-9
Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase
Background: Sema4A is a regulator of helper T cell (Th) activation and differentiation in the priming phase, which plays an important role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). However, the role of Sema4A in the effector phase remains elusive. We aimed to investigate the role of Sema4A at the effector phase in adoptively transferred EAE model. Clinical features and cytokine profiles of MS patients with high Sema4A levels were also examined in detail to clarify the correlation between Sema4A levels and disease activity of patients with MS. Methods: We adoptively transferred encephalitogenic Th1 or Th17 cells to wild type (WT) or Sema4A-deficient (Sema4A KO) mice and assessed severity of symptoms and cellular infiltration within the central nervous system (CNS). In addition, we analyzed clinical and radiological features (n = 201), levels of serum IFN-γ and IL-17A (n = 86), complete remission ratio by IFN-β (n = 38) in all of relapsing-remitting multiple sclerosis (RRMS) patients enrolled in this study. Results: Sema4A KO recipient mice receiving Th17-skewed WT myelin oligodendrocyte glycoprotein (MOG)-specific encephalitogenic T cells showed a significant reduction in the clinical score compared to the WT recipient mice. However, Sema4A KO recipient mice showed similar disease activity to the WT recipient mice when transferred with Th1-skewed encephalitogenic T cells. Bone marrow chimeric study indicated that Sema4A expressed on hematopoietic cells, but not the CNS resident cells, are responsible for augmenting Th17-mediated neuroinflammation. Additionally, in contrast to comparable IFN-γ levels, IL-17A is significantly higher in RRMS patients with high Sema4A level than those with low Sema4A patients with high Sema4A levels showed earlier disease onset, more severe disease activity and IFN-β unresponsiveness than those with low Sema4A levels. Conclusions: Sema4A is involved not only in the Th cell priming but also in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase, which could contribute to the higher disease activity observed in RRMS patients with high serum Sema4A levels.
- 13 March 2020
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 17 (1) , 1-9
Open AccessSema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase
Background: Sema4A is a regulator of helper T cell (Th) activation and differentiation in the priming phase, which plays an important role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). However, the role of Sema4A in the effector phase remains elusive. We aimed to investigate the role of Sema4A at the effector phase in adoptively transferred EAE model. Clinical features and cytokine profiles of MS patients with high Sema4A levels were also examined in detail to clarify the correlation between Sema4A levels and disease activity of patients with MS. Methods: We adoptively transferred encephalitogenic Th1 or Th17 cells to wild type (WT) or Sema4A-deficient (Sema4A KO) mice and assessed severity of symptoms and cellular infiltration within the central nervous system (CNS). In addition, we analyzed clinical and radiological features (n = 201), levels of serum IFN-γ and IL-17A (n = 86), complete remission ratio by IFN-β (n = 38) in all of relapsing-remitting multiple sclerosis (RRMS) patients enrolled in this study. Results: Sema4A KO recipient mice receiving Th17-skewed WT myelin oligodendrocyte glycoprotein (MOG)-specific encephalitogenic T cells showed a significant reduction in the clinical score compared to the WT recipient mice. However, Sema4A KO recipient mice showed similar disease activity to the WT recipient mice when transferred with Th1-skewed encephalitogenic T cells. Bone marrow chimeric study indicated that Sema4A expressed on hematopoietic cells, but not the CNS resident cells, are responsible for augmenting Th17-mediated neuroinflammation. Additionally, in contrast to comparable IFN-γ levels, IL-17A is significantly higher in RRMS patients with high Sema4A level than those with low Sema4A patients with high Sema4A levels showed earlier disease onset, more severe disease activity and IFN-β unresponsiveness than those with low Sema4A levels. Conclusions: Sema4A is involved not only in the Th cell priming but also in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase, which could contribute to the higher disease activity observed in RRMS patients with high serum Sema4A levels.
- 1 November 2019
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (11) , 1330-1331
Lamina Cribrosa Pore Diameter and Spaceflight-Associated Neuro-ocular Syndrome
To the Editor Recently, Scott et al proposed a potentially simple treatment for spaceflight-associated neuro-ocular syndrome (SANS) with commercially available
- 1 November 2019
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (11) , 1330-1331
Lamina Cribrosa Pore Diameter and Spaceflight-Associated Neuro-ocular Syndrome
To the Editor Recently, Scott et al proposed a potentially simple treatment for spaceflight-associated neuro-ocular syndrome (SANS) with commercially available